A recent study testing the therapeutic potential of ACE2‐Fc fusion, in which they administered proteins 12h after viral infection, obtained promising results in a hamster COVID‐19 model.[71] However, the dose of SARS‐CoV‐2 viruses used in this study was not high enough as it did not cause any death in control animals. The gene discussed is ACE2; the disease is viral infectious disease.